This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ross, J. Search for Related Content PubMed PubMed Citation Articles by Ross, J., Jr Related Collections Contractile function Cardiovascular Pharmacology Growth factors/cytokines Heart failure - basic studies

(Circulation. 1999;99:15-17.)
© 1999 American Heart Association, Inc.

Editorial

Growth Hormone, Cardiomyocyte Contractile Reserve, and Heart Failure

John Ross, Jr, MD

From the Division of Cardiology, Department of Medicine, University of California at San Diego.

Correspondence to John Ross, Jr, MD, University of California San Diego, Department of Medicine 0613B, 9500 Gilman Dr, La Jolla, CA 92093-0613.

Key Words: Editorials • growth substances • heart failure • myocytes

In this issue of Circulation, Tajima et al¹ report that recombinant human growth hormone (GH) (3.5 mg · kg^-1 · d^-1) given for 2 weeks, while not affecting baseline function, restored myocardial contractile reserve in cardiomyocytes isolated from rats 4 to 6 weeks after myocardial infarction (MI) compared with vehicle-treated post-MI rats. In addition, the peak of the Ca²⁺ transient, which was normal at baseline in both GH- and vehicle-treated rats, was depressed in response to increased external Ca²⁺ (3.5 mm/L) in vehicle-treated rats, whereas in the GH-treated group, increased Ca²⁺ restored the peak at the Ca²⁺ transient, as well as cardiomyocyte contractile function. Also, in the GH-treated post-MI hearts, mRNA and protein levels of sarcoplasmic reticulum Ca²⁺ ATPase 2 (SERCA-2) were increased,¹ which lends support to the proposed mechanism for restoration of contractile reserve, because only a small increase in the expression of SERCA-2 protein was reported to enhance myocardial contractility in transgenic mice.² The authors indicate that cardiomyocytes were used to obviate effects of altered loading on the heart by the vasodilator actions of GH, and the dose of GH used was said to be sufficiently low to avoid myocardial hypertrophy. This study is the first to analyze the effects of GH in cardiomyocytes from postinfarction rats and provides convincing data concerning a beneficial effect of GH on contractile reserve. It also begins to shed light on mechanisms involved in the effects of GH on myocardial function. However, some of the findings in this study raise . . . [Full Text of this Article]

This article has been cited by other articles:

				T.-B. Liu, P. W. M. Fedak, R. D. Weisel, T. Yasuda, G. Kiani, D. A. G. Mickle, Z.-Q. Jia, and R.-K. Li Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2840 - H2849. [Abstract] [Full Text] [PDF]

				S. D. Anker, M. Volterrani, C.-D. Pflaum, C. J. Strasburger, K. J. Osterziel, W. Doehner, M. B. Ranke, P. A. Poole-Wilson, A. Giustina, R. Dietz, et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone J. Am. Coll. Cardiol., August 1, 2001; 38(2): 443 - 452. [Abstract] [Full Text] [PDF]

				S. Fazio, A. Cittadini, B. Biondi, E. A. Palmieri, G. Riccio, F. Bonè, U. Oliviero, and L. Saccà Cardiovascular Effects of Short-Term Growth Hormone Hypersecretion J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 179 - 182. [Abstract] [Full Text]

				G. Olivetti, E. Cigola, R. Maestri, C. Lagrasta, D. Corradi, and F. Quaini Recent advances in cardiac hypertrophy Cardiovasc Res, January 1, 2000; 45(1): 68 - 75. [Full Text] [PDF]

				T. Ryoke, Y. Gu, L. Mao, M. Hongo, R. G. Clark, K. L. Peterson, and J. Ross Jr Progressive Cardiac Dysfunction and Fibrosis in the Cardiomyopathic Hamster and Effects of Growth Hormone and Angiotensin-Converting Enzyme Inhibition Circulation, October 19, 1999; 100(16): 1734 - 1743. [Abstract] [Full Text] [PDF]

				W.-L. Lee, J.-W. Chen, C.-T. Ting, T. Ishiwata, S.-J. Lin, M. Korc, and P. H. Wang Insulin-Like Growth Factor I Improves Cardiovascular Function and Suppresses Apoptosis of Cardiomyocytes in Dilated Cardiomyopathy Endocrinology, October 1, 1999; 140(10): 4831 - 4840. [Abstract] [Full Text]

				C. Lu, G. Schwartzbauer, M. A. Sperling, S. U. Devaskar, S. Thamotharan, P. D. Robbins, C. F. McTiernan, J.-L. Liu, J. Jiang, S. J. Frank, et al. Demonstration of Direct Effects of Growth Hormone on Neonatal Cardiomyocytes J. Biol. Chem., June 15, 2001; 276(25): 22892 - 22900. [Abstract] [Full Text] [PDF]